Admen: fixing DDMAC is more vital than user fees

Share this article:
The Coalition for Healthcare Communication says it's too soon to talk about user fees to fund ad reviews through the FDA's DDMAC. An agreement reportedly reached between industry and the FDA would provide $6.25 million in user fees in fiscal year 2008 to fund review of TV spots before they air.

“New money for DDMAC reviews puts the cart before the horse,” according to Coalition for Healthcare Communication executive director John Kamp.

He said the coalition's citizen petition last March “outlined major concerns about the FDA's DTC review process that first must be addressed. For example, the process should be much more consistent and predictable. Once there is agreement that the DTC review process better meets the needs of patients and professionals, then everyone can better assess how best to fully fund it.”

At the time the petition was submitted, Kamp said the FDA's current ad rules require complicated information that many consumers cannot understand or use on a practical basis.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...